AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)

Analyst Ratings

Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.35 (135.00% upside)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
DateFirmActionRatingPrice TargetActions
7/7/2016FBR & CoReiterated RatingOutperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2015Royal Bank Of CanadaUpgradeUnderperform -> Sector Perform$2.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.09)$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.16)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.25)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2015Q314($0.28)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.23)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.44)($0.35)$1.75 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.40)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.13)($0.13)($0.13)
Q2 20161($0.15)($0.15)($0.15)
Q3 20161($0.18)($0.18)($0.18)
Q4 20161($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
DateHeadline
07/29/16 08:08 PMBrokers Issue Average Price Target Of 2.49 On AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - FTSE News
07/26/16 02:32 PMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Updated Price ... - FTSE News
07/23/16 02:39 PMStock Up Nicely This Week: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - TGP
07/21/16 02:39 PMAVEO Pharmaceuticals Inc (NASDAQ:AVEO) Stock Technicals at Critical Inflection Point - CML News
07/20/16 10:45 AMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Short Interest Increased By 12.87% - Consumer Eagle
07/20/16 10:45 AMStock Moving Lower for the Month; Investor Update on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Engelwood Daily
07/20/16 10:45 AMIs Selling AVEO Pharmaceuticals, Inc. Here a Winning Strategy? The Stock Formed Double Bottom Chart Pattern - Consumer Eagle
07/19/16 02:40 PMCobalt International Energy (NYSE:CIE) Went Up 0.63%: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Ingles Markets ... - KC Register
07/19/16 02:40 PMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Fundamental Star ... - CML News
07/19/16 11:01 AMETF’s with exposure to AVEO Pharmaceuticals, Inc. : July 19, 2016 -
07/13/16 08:08 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Shorted Shares Decreased By 30.26% - Consumer Eagle
07/13/16 02:41 PMAVEO Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/12/16 02:45 PMAveo Pharmaceuticals Inc Stock Decreased as Institutional Investors Exit - Consumer Eagle
07/10/16 07:25 AMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 02:36 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Shorts Decreased by 30.26% After Short Covering - Press Telegraph
07/07/16 10:34 AMAveo pharmaceuticals, Inc. - product pipeline review report for 2016 published by leading research firm
07/06/16 01:07 PMETF’s with exposure to AVEO Pharmaceuticals, Inc. : July 6, 2016 -
07/06/16 07:27 AMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Current Analyst Ratings - Fiscal Standard
07/04/16 02:38 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Shorted Shares Decreased By 30.26% - Press Telegraph
07/04/16 07:31 AMBroker Outlook For The Week Ahead AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Fiscal Standard
06/27/16 07:23 AMNext Weeks Broker Price Targets For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Fiscal Standard
06/25/16 02:39 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Covered 30.26% of Their Shorts - Engelwood Daily
06/23/16 04:12 PMNew Broker Ratings For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - FTSE News
06/23/16 10:30 AMSmall-Cell Lung Cancer Pipeline Market 2016 Global Company Profiles Research
06/22/16 07:27 AMReport delivers insight into the small-cell lung cancer therapeutics drugs and companies pipeline review
06/17/16 10:36 AMAVEO PHARMACEUTICALS INC : Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/16/16 07:02 AMBRIEF-Aveo Pharmaceuticals says sale of 37.1 mln shares by stockholders - Reuters
06/15/16 04:24 PMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure -
06/15/16 06:29 AMAVEO to Present at the 2016 JMP Securities Life Science Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference ...
06/08/16 09:01 PMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Updated Price Targets - FTSE News
06/08/16 03:05 PMWill AVEO Pharmaceuticals (AVEO) Continue to Surge Higher? - Nasdaq
06/08/16 04:52 AMWill AVEO Pharmaceuticals (AVEO) Continue to Surge Higher? -
06/07/16 10:52 AMHead and neck cancer squamous cell carcinoma pipeline market review 2016 made available by top research firm
06/03/16 02:10 PMETF’s with exposure to AVEO Pharmaceuticals, Inc. : June 3, 2016 -
06/02/16 11:23 AMLatest Price movements of Stocks: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) , Stryker Corporation (NYSE:SYK) - Street Updates - Latest Price movements of Stocks: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) , Stryker Corporation (NYSE:SYK)Street UpdatesOn 6/1/2016, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) highlighted upward shift of +14.00% or +0.13 points to $1.09. The company traded a volume of 1.38 million shares over average volume of 239.87 thousand shares. Trailing twelve month period, the ...and more »
06/02/16 11:23 AMAVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)'s AGM: This Is What Shareholders Need To Know - Scibility Media - AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)'s AGM: This Is What Shareholders Need To KnowScibility MediaAt its recent annual shareholder meeting, AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) got its shareholders to approve the nominees to its board of directors. The company also secured ratification of Ernst & Young LLP as its independent public accountant.
06/02/16 11:23 AMWhat should one expect from? - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), First Horizon National Corporation ... - Beacon Chronicle - What should one expect from? - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), First Horizon National Corporation ...Beacon ChronicleThe Previous Year EPS of this Quarter is -$0.1. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) currently has High Price Target of $3. The Low and Mean Price Targets are $1.7 and $2.35 respectively. These price targets are a consensus analysis of 2 brokers.and more »
06/01/16 02:45 PMBroker Watchlist: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Share Trading News - Broker Watchlist: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Share Trading News05/19/2016 – Piper Jaffray began new coverage on AVEO Pharmaceuticals, Inc. giving the company a “overweight” rating. They now have a USD 1.7 price target on the stock. 03/30/2016 – FBR Capital Markets began new coverage on AVEO Pharmaceuticals ...AVEO Pharmaceuticals Shares Jump 15% as Growth Equity Opportunities Fund Discloses 29.6% Stake (NASDAQ ...Sonoran Weekly Reviewall 2 news articles »
06/01/16 02:45 PMStocks on the Move: Galena Biopharma Inc (NASDAQ:GALE), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Viking ... - The Point Review - The Point ReviewStocks on the Move: Galena Biopharma Inc (NASDAQ:GALE), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Viking ...The Point ReviewShares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 12.64% to $1.07 at 11:27 AM EDT. The stock exchanged hands of 856,993 shares recently versus average trading capacity of 166,650 shares. However recently the stock touch highest trading ...and more »
05/31/16 02:57 PMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/28/16 01:18 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Increased By 58.72% Their Shorts - Wall Street Hints and News - Aveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Increased By 58.72% Their ShortsWall Street Hints and NewsAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $53.67 million. The Company's platform delivers insights into cancer and related disease. It currently has negative earnings. The Company's product candidates ...and more »
05/26/16 01:21 PMBRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell ... - Reuters - BRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell ...ReutersMay 26 Aveo Pharmaceuticals Inc. * Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma. * Top line readout of study is currently projected for Q1 of 2018 Source text for Eikon: Further company coverage ...
05/26/16 01:21 PMPiper Jaffray Initiates Coverage on AVEO Pharmaceuticals to Overweight - Trade Calls - Piper Jaffray Initiates Coverage on AVEO Pharmaceuticals to OverweightTrade CallsIn a different note, FBR Capital said it Initiates Coverage on AVEO Pharmaceuticals, according to a research note issued on Mar 30, 2016. The shares have been rated 'Outperform' by the firm. AVEO Pharmaceuticals (AVEO) made into the market gainers list ...and more »
05/26/16 01:21 PMCompany Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Announces Dosing of First Patient in the Pivotal ... - Smarter Analyst - Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Announces Dosing of First Patient in the Pivotal ...Smarter AnalystAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory ...and more »
05/26/16 10:13 AMAVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/26/16 06:17 AMAVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma - [at noodls] - http://www.businesswire.com/news/home/20160526005388/en/ The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or metastatic RCC who have failed at least two prior regimens, ...
05/24/16 11:52 AMTrending Tickers: AVEO Pharmaceuticals(NASDAQ:AVEO), Argos Therapeutics(NASDAQ:ARGS), Express Scripts ... - KC Register - Trending Tickers: AVEO Pharmaceuticals(NASDAQ:AVEO), Argos Therapeutics(NASDAQ:ARGS), Express Scripts ...KC RegisterOn May 18, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a ...
05/22/16 12:55 PMAlpha One Assigns Impact Score Of 0 To AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Investor Newswire - Alpha One Assigns Impact Score Of 0 To AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Investor NewswireAlpha One analyzed the various web articles published on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), and thereafter it gave company a daily sentiment score of 0. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/20/16 11:38 AMRecent research: 2015 H2 neck cancer pipeline market analysis - Inc. , AstraZeneca Plc , ATLAB Pharma SAS , AVEO Pharmaceuticals, Inc. , Bayer AG , Bexion Pharmaceuticals, LLC. , BIND Therapeutics, Inc. , Bio-Path Holdings, Inc. , BioDiem Ltd , Bionovis SA , Biotest AG , Boehringer Ingelheim GmbH , Boston Biomedical ...
05/19/16 12:04 PMAVEO PHARMACEUTICALS INC Financials -

Social

About AVEO Pharmaceuticals

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company. The Company's platform has delivered insights into cancer and related disease. The Company's Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company's product candidates include AV203, Ficlatuzumab, Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AVEO
  • CUSIP: 05358810
Key Metrics:
  • Previous Close: $1.00
  • 50 Day Moving Average: $0.97
  • 200 Day Moving Average: $0.97
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $58.18M
  • Beta: 0.67
  • Current Year EPS Consensus Estimate: $-0.51 EPS
  • Next Year EPS Consensus Estimate: $-0.43 EPS
Additional Links:
AVEO Pharmaceuticals (NASDAQ:AVEO) Chart for Saturday, July, 30, 2016